TY - JOUR
T1 - Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy
AU - Ramos Perez, Jorge M.
AU - Patel, Keyur P.
AU - Loghavi, Sanam
AU - Garcia-Manero, Guillermo
AU - Borthakur, Gautam
AU - Jabbour, Elias
AU - Wierda, William
AU - Pierce, Sherry
AU - Brandt, Mark
AU - Kornblau, Steven
AU - Kadia, Tapan
AU - Daver, Naval
AU - DiNardo, Courtney D.
AU - Jain, Nitin
AU - Yilmaz, Musa
AU - Short, Nicholas
AU - Verstovsek, Srdan
AU - Ferrajoli, Alessandra
AU - Andreeff, Michael
AU - Konopleva, Marina
AU - Rivera, Daniel
AU - McCue, David
AU - Kantarjian, Hagop M.
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Acute promyelocytic leukemia (APL) is characterized by the chromosomal translocation t(15;17) and the resulting gene PML-RARA, used for measurable residual disease (MRD) monitoring. Despite highly effective therapy for APL, MRD monitoring practices are not fully established. We aimed to assess the value of MRD monitoring by RT-qPCR in patients with APL treated with ATRA and arsenic trioxide +/– GO. We reviewed 223 patients with APL treated with this regimen. RT-qPCR for PML-RARA was measured every 3 months, and at 12, 18, and 24 months after therapy. Seven patients relapsed. Time to relapse was 7.9–12.4 months in 6 patients, and one patient relapsed after 79.5 months. These data show that MRD monitoring may be important for the detection of relapse in patients treated with this regimen within one year after completing therapy, however, since late molecular relapse is rare, our data suggest a low value of MRD monitoring beyond that first year.
AB - Acute promyelocytic leukemia (APL) is characterized by the chromosomal translocation t(15;17) and the resulting gene PML-RARA, used for measurable residual disease (MRD) monitoring. Despite highly effective therapy for APL, MRD monitoring practices are not fully established. We aimed to assess the value of MRD monitoring by RT-qPCR in patients with APL treated with ATRA and arsenic trioxide +/– GO. We reviewed 223 patients with APL treated with this regimen. RT-qPCR for PML-RARA was measured every 3 months, and at 12, 18, and 24 months after therapy. Seven patients relapsed. Time to relapse was 7.9–12.4 months in 6 patients, and one patient relapsed after 79.5 months. These data show that MRD monitoring may be important for the detection of relapse in patients treated with this regimen within one year after completing therapy, however, since late molecular relapse is rare, our data suggest a low value of MRD monitoring beyond that first year.
KW - APL
KW - ATRA plus ATO
KW - MRD monitoring
UR - http://www.scopus.com/inward/record.url?scp=85117311661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117311661&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1992757
DO - 10.1080/10428194.2021.1992757
M3 - Article
C2 - 34668451
AN - SCOPUS:85117311661
SN - 1042-8194
VL - 63
SP - 672
EP - 675
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -